Physician profile

Michael Katin

Radiation Oncology · Woonsocket, RI

NPI 1811994999

$236.03

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$41.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Reflexion Medical, INC. $41.71 2024 Reflexion Medical Radiotherapy System
Merck Sharp & Dohme LLC $33.37 2021-2022
Boston Scientific Corporation $24.97 2022
Pharmacyclics LLC, An Abbvie Company $24.93 2022
Blue Earth Diagnostics $22.29 2021
Myovant Sciences INC. $20.08 2021
Dendreon Pharmaceuticals LLC $18.85 2019
Pfizer INC. $18.42 2020
Bayer Healthcare Pharmaceuticals INC. $15.71 2020
Sun Pharmaceutical Industries INC. $15.70 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Katin

$236.03

in general payments reported 2019-2025

Years
2019-2024
Top company
Reflexion Medical, INC.

https://glasscript.com/doctor/386403/michael-katin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.